K-1728
Asset
Pan-mutant selective inhibitor of PI3Kα sparing wild-type PI3Kα
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- PIK3CA
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Cancer
Preclinical, prnewswire.com, 6 Oct 2026
Vascular malformations
Preclinical, prnewswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.